Intersect ENT Stock Forecast, Price & News

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XENT stock has decreased by 5.8% and is now trading at $20.25.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intersect ENT.

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Intersect ENT.

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Thursday, November, 5th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.10. The medical equipment provider had revenue of $22.72 million for the quarter, compared to analysts' expectations of $21.78 million. Intersect ENT had a negative net margin of 71.96% and a negative return on equity of 55.81%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.41) EPS.
View Intersect ENT's earnings history.

Intersect ENT issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, November, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $26.991-28.579 million, compared to the consensus revenue estimate of $29 million.

8 Wall Street analysts have issued 12-month target prices for Intersect ENT's shares. Their forecasts range from $10.00 to $32.00. On average, they expect Intersect ENT's stock price to reach $20.57 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts' price targets for Intersect ENT.

Intersect ENT saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,400,000 shares, an increase of 34.6% from the October 15th total of 1,040,000 shares. Based on an average daily trading volume, of 240,600 shares, the days-to-cover ratio is currently 5.8 days. Currently, 4.5% of the shares of the company are sold short.
View Intersect ENT's Short Interest.

Some companies that are related to Intersect ENT include Cantel Medical (CMD), NuVasive (NUVA), Inovio Pharmaceuticals (INO), AtriCure (ATRC), Pulmonx (LUNG), Silk Road Medical (SILK), Axonics Modulation Technologies (AXNX), Cardiovascular Systems (CSII), Atrion (ATRI), Cerus (CERS), Luminex (LMNX), GenMark Diagnostics (GNMK), OrthoPediatrics (KIDS), OraSure Technologies (OSUR) and Alphatec (ATEC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil Capped ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Intersect ENT's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.10%), First Light Asset Management LLC (3.63%), Jennison Associates LLC (3.08%), Neuberger Berman Group LLC (2.82%), Great Point Partners LLC (2.29%) and State Street Corp (2.16%). Company insiders that own Intersect ENT stock include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Robert H Binney, Jr, Susan P Stimson and Thomas A West.
View institutional ownership trends for Intersect ENT.

XENT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, AQR Capital Management LLC, BlackRock Inc., Aigen Investment Management LP, Wells Fargo & Company MN, Neuberger Berman Group LLC, Morgan Stanley, and Mackay Shields LLC.
View insider buying and selling activity for Intersect ENT.

XENT stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Jennison Associates LLC, Assenagon Asset Management S.A., Voloridge Investment Management LLC, ExodusPoint Capital Management LP, Jackson Creek Investment Advisors LLC, Sei Investments Co., and Gabelli Funds LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT.

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XENT stock can currently be purchased for approximately $20.25.

Intersect ENT has a market capitalization of $662.56 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 402 workers across the globe.

The official website for Intersect ENT is www.intersectent.com.

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]